Efficacy Observation Of Urinary Kallikrein Injection In Patients With Acute Cerebral Infarction And Its Effect On Promoting Angiogenesis

Objective: To assess the efficacy and safety of urinary kallikreininjection in treating patients with acute ischemic stroke, and to explore itseffect on promoting angiogenesis.Methods: Forty cases who come from the second hospital of hebeimedical university suffering from cerebral infarction between6and72h ofonset were randomly assigned into the conventional group (n=20) andkallikrein group (n=20). The conventional group was given conventionaltreatment, whereas the kallikrein group was given both conventional treatmentand urinary kallikrein injection over the course of14days. The HIHSS scorewas evaluated before and after treatment. The concentration of bFGF, TXB2and PGF1αwere tested by ELISA at1and14days after stroke onset.Results:1General information: There were totally40cases meeting the criteriapatients including,20cases of conventional group and20cases of kallikreingroup.20health people were involved in this test.There was no difference inthe general situation such as age, gender, concomitant disease, time betweenonset and healing NIHSS score before healing.(P＞0.05).2The NIHSS scores in the two groups were no statistical differencebefore treating, statistical differences emerged after treating between twogroups. The improvement of NIHSS score in the kallikrein group was greaterthan the conventional group (P<0.05). And the adverse reaction rate in the twogroups were no statistical difference.3The concentration of bFGF in the plasma of people suffering fromcerebral infarction in three groups: comparing to the health group, theconcentration of bFGF was significantly increased in conventional group and kallikrein group (P<0.05); comparing to conventional group, the concentrationof bFGF was greatly increased in kallikrein group (P<0.05).4The concentration of TXB2and PGF1α in the plasma of peoplesuffering from cerebral infarction in three groups: comparing to the healthgroup, the concentration of TXB2was significantly increased in conventionalgroup and kallikrein group (P<0.05); comparing to conventional group, theconcentration of TXB2was greatly decreased in kallikrein group (P<0.05).The difference of the concentration of PGF1αwas not significant.5The ratio of PGF1α/TXB2in the plasma of people suffering fromcerebral infarction in three groups: comparing to the health group, the ratio ofPGF1α/TXB2was decreased in conventional group and kallikrein group(P<0.05); comparing to conventional group, the ratio of PGF1α/TXB2wasgreatly increased in kallikrein group (P<0.05).Conclusions:1Urinary kallikrein showed a relatively conclusive effect on theomprovement of cerebral functions in patients with acute cerebral infaction.The side-effects were minimal and easy to be controlled.2Urinary kallikrein showed a best effect when used in72hour afteracute cerebral infarction. Urinary kallikrein could decrease the expression ofTXB2and upregulate the expression of bFGF, as well as the ratio of PGF1α/TXB2at the same time in people suffering from cerebral infarction. Theangiogenesis effect of Urinary kallikrein may be achieved by the activation ofbFGF and upregulate the ratio of PGF1α/TXB2.